Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 13;13:6037. doi: 10.1038/s41467-022-33268-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a SMIFH2, not CK666, inhibits actinification. n = 2 independent experiments; two-way ANOVA [(−) NMDA vs (+) NMDA, F (1, 6) = 513.2; p = 0.0001; ctrl vs SMIFH2 vs CK666, F (2, 6) = 101, p = 0.0001], with Tukey’s post hoc multiple comparison analysis (p < 0.0001 NMDA vs NMDA w/ SMIFH2; n.s. p = 0.9168 NMDA vs NMDA w/ CK666). b INF2 immunoreactivity in neurons (NeuN). Arrows: distal (yellow) and proximal (blue) dendrites (MAP2), enlarged in lower panels. Scale bar, 12 µm (upper panels), 5 µm (lower panels). c INF2 immunoreactivity is higher in early-actinified than non-actinified neurons. Blue arrows: neuronal soma. Scale bar: 20 µm. n = 2 independent experiments; unpaired t-test,two-tailed (p = 0.0175). d Wildtype INF2 (INF2_WT) enhances NMDA-induced actinification; constitutively active INF2 (INF2_CA) actinifies without NMDA. n = 4 independent experiments; two-way ANOVA [(−) NMDA vs (+) NMDA, F (1, 18) = 1645; p = 0.0001; eGFP vs INF2_WT vs INF2_CA, F (2, 18) = 2394, p = 0.0001], with Tukey’s post hoc multiple comparison analysis (p = 0.0001 eGFP +/− NMDA; p = 0.0001 INF2_WT +/− NMDA; n.s. p = 0.999 INF2_CA +/− NMDA). e INF2 shRNA prevents actinification; rescue by shRNA-resistant INF2_WT. n = 2 independent experiments; two-way ANOVA [(−) NMDA vs (+) NMDA, F (1, 6) = 481.1; p = 0.0001; empty v. vs INF2shRNA vs INF2shRNA + INF2_WT, F (2, 6) = 100.6, p = 0.0001], with Tukey’s post hoc multiple comparison analysis (p = 0.0001 empty v. +/− NMDA; n.s. p = 0.7496 INF2shRNA +/− NMDA; p = 0.0001 INF2shRNA & INF2_WT +/− NMDA). f Jasplakinolide (JASP) prevents NMDA-induced actinification (GFP-F-tractin). n = 2 independent experiments; two-way ANOVA [(−) NMDA vs (+) NMDA, F (1, 4) = 76.34; p = 0.0009; (−) JASP vs (+) JASP, F (1, 4) = 76.34; p = 0.0009]. Scale bar, 4 µm. g C646 formin-dependent actinification, despite NMDAR antagonists (APV + MK801). n = 3 independent experiments; two-way ANOVA [(−)C646 vs (+) C646, F (1, 12) = 144.4; p = 0.0001; vehicle vs NMDA antagonists vs SMIFH2, F (2, 12) = 21.2; p = 0.0001], with Tukey’s post hoc multiple comparison analysis (p < 0.0001 vehicle +/− C646; (p < 0.0001 NMDAR anta +/− C646; n.s. p = 0.5596 SMIFH2 +/− C646). Scale bar, 12 µm. All data are mean ± SEM. Source data are provided as source data file.